Novobanco Partners With Feedzai to Turbocharge Customer Engagement
Partnership reiterates Novobanco’s commitment to delivering a market leading and seamless experience for the consumer…
News
CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
Promising Efficacy and Safety With Four-Week Extended Dosing Data Shows Dose-Dependent Reduction of LDH and…
Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture “Insighta” for Breakthrough Multi-Cancer Early Detection Screening
HONG KONG, Jun 26, 2023 – (ACN Newswire) – Prenetics Global Limited ( https://ir.prenetics.com )…
BrainChip Selects IPro Silicon IP to Serve Israel’s High Growth AI Market
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first…
Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
ALTUVIIIOTM late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia…
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis…
SPR Therapeutics Named a Top Workplace for Second Consecutive Year
– Company maintains focus on employee engagement and success while experiencing dynamic growth – CLEVELAND,…
Lerner & Rowe Announces Car Accident Injury Legal Representation In Albuquerque
Albuquerque, New Mexico–(Newsfile Corp. – June 24, 2023) – Lerner & Rowe Injury Attorneys ,…
Hodgson Law Offices Announces Divorce Attorney Services In Spokane County
Hodgson Law Offices announces legal counsel and representation services for couples going through a divorce….
Novo Nordisk A/S: New data show once-weekly insulin icodec met additional endpoints in adults with type 2 diabetes in phase 3a trials
After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at…
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Siemens Energy AG (SMEGF, SMNEY) on Behalf of Investors
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical…
Tashi: True Serverless Gaming is Here
SINGAPORE, Jun 24, 2023 – (ACN Newswire) – Tashi, an innovative company developing proprietary technology…
From General to Personalized Care: GE HealthCare is Focused on Disease Detection and More Holistic and Effective Treatment Options
The company will showcase its latest innovative solutions to enable rapid diagnosis, Theranostics, and precision…
Enterin Presents Data Demonstrating Strong Benefit of ENT-03 on Body Weight, Adiposity and Blood Glucose Vs. Semaglutide in a Diet Induced Obesity Mouse Model
Data presented at the American Diabetes Association 83rd Scientific Sessions PHILADELPHIA, June 24, 2023 (GLOBE…
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
– Data Presented During Oral Session at EASL 2023 Demonstrate Fazirsiran’s Promising Impact on Key…
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection…
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat,…
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted…
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
Daix (France), Long Island City (New York, United States), June 24, 2023 – Inventiva (Euronext…